BioNTech SE Sponsored ADR $BNTX Shares Sold by Capital International Inc. CA

Key Points

• Capital International Inc. CA cut its BioNTech holding by 37.6% in Q3, selling 176,809 shares and now owns 293,208 shares (~0.12%) valued at $28.9M.
• BioNTech beat Q4 expectations and ends FY2025 with a strong cash position (~€17.2B) and multiple 2026 oncology catalysts, but founder departures, a reduced FY2026 revenue guide (€2.0–2.3B), a FY2025 net loss (€1.1B) and a shareholder probe have driven the stock down ~17.9%.
• Analyst sentiment is mixed-to-positive with a consensus "Moderate Buy" and a $136 target (10 Buys, 4 Holds, 1 Sell), though some firms have trimmed targets while maintaining constructive ratings.

Capital International Inc. CA trimmed its position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 37.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 293,208 shares of the company's stock after selling 176,809 shares during the quarter. Capital International Inc. CA owned approximately 0.12% of BioNTech worth $28,916,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Victory Capital Management Inc. increased its holdings in BioNTech by 97.0% in the third quarter. Victory Capital Management Inc. now owns 413,685 shares of the company's stock valued at $37,531,000 after buying an additional 203,700 shares in the last quarter. APG Asset Management N.V. grew its position in shares of BioNTech by 3.0% during the 3rd quarter. APG Asset Management N.V. now owns 54,700 shares of the company's stock valued at $5,395,000 after acquiring an additional 1,600 shares during the period. Huntington National Bank increased its stake in shares of BioNTech by 1,266.7% in the 3rd quarter. Huntington National Bank now owns 410 shares of the company's stock valued at $40,000 after purchasing an additional 380 shares in the last quarter. Fox Run Management L.L.C. raised its holdings in BioNTech by 242.8% in the 3rd quarter. Fox Run Management L.L.C. now owns 9,750 shares of the company's stock worth $962,000 after purchasing an additional 6,906 shares during the period. Finally, Optiver Holding B.V. purchased a new position in BioNTech during the third quarter worth approximately $198,000. 15.52% of the stock is owned by hedge funds and other institutional investors.

More BioNTech News

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: Company ends FY2025 with a very strong cash position (cash, cash equivalents and securities ~€17.2B), which management says de‑risks execution and funds pipeline investments. Press Release
• Positive Sentiment: BioNTech highlighted multiple upcoming oncology catalysts — six late‑stage readouts expected in 2026 and large Phase 3 activity for the PD‑L1/VEGF‑A bispecific (pumitamig) in partnership with Bristol Myers — providing potential upside if trials read out positively. Press Release
• Positive Sentiment: Q4 results beat near‑term expectations on both EPS and revenue (Q4 revenue ~$1.06B vs. ~$942M consensus; EPS loss narrower than expected), showing operational resilience despite YoY revenue declines. Earnings Highlights
• Neutral Sentiment: Co‑founders will form an independent next‑generation mRNA company; BioNTech will contribute certain rights/technologies and take a minority stake with potential milestone and royalty upside — the deal reduces internal focus on those programs but preserves some upside. Company Announcement
• Neutral Sentiment: Jefferies trimmed its price target (from $151 to $138) but kept a Buy rating, signaling some analyst confidence in longer‑term upside despite the reset. Analyst Note
• Negative Sentiment: Founders Şahin and Türeci plan to depart by end‑2026 to start a new mRNA firm; markets treated the leadership exit as a governance and continuity risk, triggering selling pressure. Reuters
• Negative Sentiment: FY2026 revenue guidance was reduced to €2.0–2.3B (well below street expectations), and management signaled higher near‑term R&D/SG&A, which drove concern about near‑term growth and profitability. Guidance & Results
• Negative Sentiment: FY2025 reported a net loss (€1.1B) and a ~24% YoY revenue decline, highlighting the post‑COVID transition and amplifying sensitivity to guidance and leadership changes. Financials
• Negative Sentiment: A shareholder law firm announced an investigation into potential claims related to executive conduct, which can add legal overhang and investor uncertainty. Legal Notice

Analyst Ratings Changes

Several brokerages have recently weighed in on BNTX. Berenberg Bank reaffirmed a "buy" rating on shares of BioNTech in a research note on Friday, January 23rd. Morgan Stanley reissued an "overweight" rating on shares of BioNTech in a report on Tuesday. UBS Group upgraded shares of BioNTech to a "hold" rating in a research report on Thursday, December 4th. Bank of America reaffirmed a "buy" rating and set a $128.00 price objective on shares of BioNTech in a report on Tuesday. Finally, Jefferies Financial Group dropped their target price on shares of BioNTech from $151.00 to $138.00 and set a "buy" rating on the stock in a research report on Tuesday. Ten research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $136.00.

BioNTech Stock Down 17.9%

Shares of BNTX opened at $83.89 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.02 and a current ratio of 7.12. BioNTech SE Sponsored ADR has a one year low of $79.52 and a one year high of $124.00. The stock has a market capitalization of $18.89 billion, a price-to-earnings ratio of -31.90 and a beta of 1.51. The stock has a 50 day moving average price of $106.73 and a 200 day moving average price of $102.83.

BioNTech Company Profile

BioNTech SE NASDAQ: BNTX is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech's core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.